UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
May 11, 2005
----------------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
- --------------------------------- ------------- -------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
---------------------------------------
(Address of principal executive offices)
(631) 962-2000
---------------------------------------
(Registrant's telephone number, including area code)
N/A
---------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On May 11, 2005, OSI Pharmaceuticals, Inc. ("OSI") issued a press
release announcing the issuance of US Patent No. 6,890,898 which claims
combination therapy for modifying glucose metabolism comprising administration
of a dipeptidyl peptidase IV ("DPIV") inhibitor. The press release is attached
hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
On May 12, 2005, (OSI) Prosidion, the diabetes and obesity business
unit of OSI, issued a press release announcing that it has entered into a
worldwide non-exclusive license agreement under its DPIV patent portfolio
covering the use of DPIV inhibitors for the treatment of type 2 diabetes and
related indications. The press release is attached hereto as Exhibit 99.2 to
this Form 8-K and is incorporated herein by reference.
ITEM 9.01 EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated May 11, 2005.
99.2 Press release, dated May 12, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 16, 2005 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
--------------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated May 11, 2005.
99.2 Press release, dated May 12, 2005.